Standout Papers
- Expression pattern of the von Hippel-Lindau protein in human tissues. (1996)
Citation Impact
Citing Papers
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
2010 StandoutNobel
Alteration of enzyme specificity by computational loop remodeling and design
2009 StandoutNobel
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy
2007
Regulation of tyrosine hydroxylase promoter activity by the von Hippel–Lindau tumor suppressor protein and hypoxia‐inducible transcription factors
2003
Hallmarks of Cancer: The Next Generation
2011 Standout
Use of bromodeoxyuridine-immunohistochemistry to examine the proliferation, migration and time of origin of cells in the central nervous system
1988
Positive Psychological Well-Being and Mortality: A Quantitative Review of Prospective Observational Studies
2008
Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.
1988
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Pamidronate
1992
Ferroptosis as a p53-mediated activity during tumour suppression
2015 StandoutNature
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Cell production rates in human tissues and tumours and their significance. Part II: clinical data
2000
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
2010
The role of COX-2 inhibition in breast cancer treatment and prevention
2004
Bone and cancer: Pathophysiology and treatment of metastases
1995
Oncogenic kinase signalling
2001 StandoutNature
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis
2000
Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma
2002
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Imaging in the era of molecular oncology
2008 StandoutNature
Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study
1994
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Costimulation of Adenylyl Cyclase and Phospholipase C by a Mutantα1B-Adrenergic Receptor Transgene Promotes Malignant Transformation of Thyroid Follicular Cells1
1997 StandoutNobel
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
1995 StandoutNature
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
2010 StandoutNature
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
1999 StandoutNatureNobel
Osteoclast inhibition for the treatment of bone metastases
1993
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Neurogenesis in the adult is involved in the formation of trace memories
2001 StandoutNature
Esophageal Cancer
2003 Standout
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
1993 Standout
The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing
2003 StandoutNobel
Angiogenesis in cancer and other diseases
2000 StandoutNature
von Hippel-Lindau Disease
1997 StandoutNobel
Depression as a predictor of disease progression and mortality in cancer patients
2009
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
2012
The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix
1998 StandoutNobel
RNA travel: Tracks from DNA to cytoplasm
1993 StandoutNobel
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
1999 StandoutNature
Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)
1988
Cancer immunotherapy comes of age
2011 StandoutNature
Subjective wellbeing, health, and ageing
2014 StandoutNobel
The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer
1991
Meta-analysis when only the median survival times are known: A comparison with individual patient data results
2005
Bisphosphonates and bone metastases
1988
Structure of the Tie2 RTK Domain
2000
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
2011
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
1996 Standout
Imaging of angiogenesis: from microscope to clinic
2003
Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats
1996
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
1998
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Leukocyte-endothelial adhesion and angiogenesis in tumors
1996
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
Cancer-related inflammation
2008 StandoutNature
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
1999 Standout
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice
1996 StandoutNature
Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice
1996 Science
HIF-1α is required for development of the sympathetic nervous system
2019 StandoutNobel
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
2004 StandoutNobel
Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle.
1992
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
2001
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
1999 StandoutScienceNobel
von Hippel-Lindau Disease
2006 StandoutNobel
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).
1994 Standout
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor
2002 StandoutNobel
EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance
2019 StandoutNobel
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
The von Hippel-Lindau Tumor Suppressor Gene
2020
Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel
2001
Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
2000
Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism.
1992
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner
2016 StandoutScienceNobel
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
1999 StandoutScienceNobel
Liver Regeneration
1997 StandoutScience
von Hippel-Lindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha Translation Revealed through Use of cDNA Arrays
2003
Thermal Preconditioning Before Rat Arterial Balloon Injury
1998 StandoutNobel
mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation
2003
Fluorescent labeling of nascent RNA reveals transcription by RNA polymerase II in domains scattered throughout the nucleus
1993
Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2
1998 StandoutNobel
Identification of Putative c-Myc-Responsive Genes: Characterization of rcl, a Novel Growth-Related Gene†
1997
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
The Molecular Basis of Von Hippel-Lindau Disease
1997 StandoutNobel
Works of G.H. Blijham being referenced
Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer
1994
Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium
1996
REDUCED MORBIDITY FROM SKELETAL METASTASES IN BREAST CANCER PATIENTS DURING LONG-TERM BISPHOSPHONATE (APD) TREATMENT
1987
Cytokinetic analysis of lung cancer by in vivo bromodeoxyuridine labelling
1993
Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients
2002
Effect of tissue fixation on anti-bromodeoxyuridine immunohistochemistry.
1987
Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer
2001
CLINICAL RESEARCH ON ANTIANGIOGENIC THERAPY
1998
Chemotherapy of colorectal cancer
1991
Palliative pamidronate treatment in patients with bone metastases from breast cancer.
1993
Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease
1997
Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
1997
Aromatase and COX-2 expression in human breast cancers
2001
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
1999
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer
1997
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
1996
Expression pattern of the von Hippel-Lindau protein in human tissues.
1996 StandoutNobel
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
1999
Studies with anti-bromodeoxyuridine antibodies: II. Simultaneous immunocytochemical detection of antigen expression and DNA synthesis by in vivo labeling of mouse intestinal mucosa.
1987
An improved method for the immunocytochemical detection of bromodeoxyuridine labeled nuclei using flow cytometry
1987
Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors.
1996
An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer.
1986